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Abstract 
Aims: We aimed to assess the clinico-pathological relevance and prognostic 
significance of hepatic progenitor cell markers keratin 19 (K19), Epithelial Cell 
Adhesion Molecule (EpCAM) and CD117 (c-KIT) expression in a Caucasian 
series of hepatocellular carcinoma (HCC). 
Methods: We evaluated the immunohistochemical expression of K19, 
EpCAM and CD117 in 89 surgical specimens of HCC from Greek patients 
(mean age 66.7±11.3 years, male 75.2%) followed-up for 39.625.3 months. 
Results: K19-, EpCAM- and CD117-specific expression was detected in 
tumour cells of 10.11%, 15.38% and 3.7% HCCs, respectively. Female 
gender was correlated with EpCAM immunohistochemical expression 
(p=0.035), while no other significant relationship with clinico-pathological 
parameters was observed. K19-positivity tended to correlate with 
microvascular invasion (p=0.054). In univariate analysis, K19-positivity and 
microvascular invasion were associated with decreased recurrence-free 
(RFS) (p<0.001 and p=0.004, respectively) and overall survival (OS) (p=0.002 
and p=0.029, respectively). EpCAM- and CD117-positivity did not correlate 
with patient survival. In multivariate analysis, K19-positivity emerged as an 
independent predictor of RFS (OR=7.84, 95%CI=2.658-22.912; p<0.001) and 
OS (OR=3.845, 95%CI=1.401-10.549; p=0.009).    
Conclusions:  Our study confirms the prognostic significance of K19 
expression in Caucasian HCC providing further evidence that it may be used 
to stratify HCC according to tumour aggressiveness.  
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Introduction 
Hepatocellular carcinoma (HCC) is a neoplasm of increasing incidence and is 
the third cause of cancer-related death worldwide [1]. HCC is currently 
considered a heterogeneous entity due to substantial differences in molecular 
profile and biological behaviour.  HCC diversity also refers to the cells of origin 
since mature hepatocytes as well as hepatic progenitor cells (HPC) may be 
the target population in hepatocarcinogenesis within the context of advanced 
liver disease and cirrhosis [2]. Direct proof that primary liver carcinomas with 
mixed features derive from HPC/oval cells originate only from rodent studies 
[3], while indications from human studies were until recently limited and/or 
speculative. The strongest evidence to date that liver malignancy in humans 
may derive from HPC has been the demonstration of HPC/stem cell marker 
expression in HCC and the associated worse patient prognosis [4, 5]. 
 
Carcinomas of HPC origin and their subtypes are grouped together into the 
category of combined hepatocellular-cholangiocarcinoma according to World 
Health Organisation (WHO) 2010 classification of liver tumours [6]. Another 
recently proposed HCC subtype of assumed HPC origin is emerging defined 
by the presence of a tumour cell fraction expressing HPC markers, but not 
otherwise recognisable by routine haematoxylin-eosin (H-E) stain [7]. Several 
markers, including keratin 19 (K19), epithelial cell adhesion molecule 
(EpCAM), CD133, CD117 (c-KIT) and SALL4 have been suggested as 
indicators of HPC origin in HCCs [8]. K19, normally found in HPCs and 
cholangiocytes but not in hepatocytes, has been proven to be the most 
reliable marker for the characterization of HPCs [9, 10]. Markers of stemness 
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have been associated with increased telomere length and chromosomal 
instability [11], microvascular invasion [12], high metastatic potential [13] and 
poor survival [14-16]. There is also increasing evidence suggesting that K19 
immunohistochemical expression may be used as a prognostic marker in 
human HCC [10, 14, 17-22]. However, the majority of these studies are based 
on HCC of Asian origin. HCC with a K19-expressing cell population is not as 
yet an established entity, while controversial data regarding biological 
behaviour require further investigation at clinico-pathological and molecular 
level. 
 
Similarly, EpCAM represents a marker for stem cell/progenitor cells of adult 
human liver and oval cells in rodent liver and can be used to classify HCCs 
according to tumour aggressiveness. EpCAM expression has been 
associated with worse outcomes following liver transplantation [23] or 
resection [9, 24, 25]. Although no association has so far been established with 
regards to CD117 expression and poor prognosis, CD117 has also been 
considered as a potential marker of stem/progenitor cells in previous HCC 
studies [26-30].  
 
The objective of the present study was to examine K19, EpCAM, CD117 
expression in a series of human HCCs of Caucasian origin and their potential 
correlation with clinico-pathological parameters and patient prognosis after 
curative liver resection or transplantation. 
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Methods 
We retrospectively identified all HCC cases (explant livers and resection 
specimens) from the archives of the 1stDepartment of Pathology and the 
Laboratory of Histology-Embryology, Medical School, National and 
Kapodistrian University of Athens, between June 1996 and March 2009. We 
subsequently sought clinical details of these patients through their medical 
notes including treatment received and overall survival. In total, 113 patients 
with histologically diagnosed HCC were identified; among these 89 patients 
had sufficient clinical data and were included in the study. Clinical parameters 
of the study population were retrospectively collected.  Mean patient age was 
66.7±11.3 years (range 33-85) and 75.2% were male. 
 
Data on the aetiology of underlying chronic liver disease was available in 72 
cases and included hepatitis B virus (HBV) infection (n=30/72, 41.7%), 
hepatitis C virus (HCV) infection (n=21/72, 29.2%), alcohol-related (n=4/72, 
5.6%) and non-alcoholic steatohepatitis (8/72, 11.1%). Hepatitis B and C co-
infection was present in 5/72 cases (6.9%). Other aetiologies included 
haemochromatosis (n=2), and primary biliary cirrhosis (PBC) (n=2). In 17 
cases the underlying aetiology could not be established. Cirrhosis was 
present in 46 out of the 73 (63%) patients with background non-neoplastic 
tissue available for analysis. Thirteen patients received loco-regional 
treatment prior to resection or transplantation (transarterial 
chemoembolization-TACE n=12, radiofrequency ablation-RFA n=1).  
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Pathological variables recorded included tumour size, presence of multiple 
tumours, tumour grading according to Edmondson-Steiner [31], capsular 
invasion, microvascular and/or macrovascular invasion, and presence of 
cirrhosis in the non-neoplastic liver parenchyma. Staging was performed 
according to TNM classification (7th edition) [32]. 
 
The study was performed in accordance with National Bioethical Standards 
and ethical standards of the revised Helsinki Declaration of World Medical 
Association (2000). Appropriate consent for use of anonymised archival tissue 
for research was obtained in each case. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded 4μm-thick serial tissue sections of each 
case were preheated at 56° C, deparaffinised in xylene, rehydrated in graded 
ethanol, and then washed in phosphate buffered saline (pH=7.6). Heat 
induced antigen retrieval was performed with 10mM citrate buffer (pH 6.0) for 
12 min (for K19 and EpCAM) or with EDTA (pH=9) for 8 min (for CD117) in a 
microwave oven (600w). Immunohistochemistry was performed using the 
NovoLink Polymer Detection System (Novocastra Laboratories-Menarini, 
Athens, Greece) and mouse monoclonal antibodies to K19 (clone A53-
B/A.2.26, Thermo Scientific, UK) (1/50 dilution), EpCAM (ESA Ab-7, MOC31, 
Neomarkers, Freemont, CA, USA) (1/50 dilution), and CD117 (clone 2E4, 
Zymed, San Francisco, CA, USA) (3/100 dilution) with overnight incubation at 
4°C. 3’,3’-diaminobenzidine (DAB) was used as chromagen and light 
haematoxylin as counterstain. 
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Cholangiocytes in non-neoplastic liver parenchyma present in most sections 
served as internal positive control for K19 and EpCAM, while mast cells were 
used as internal positive control for CD117. In negative control sections of 
each case, the primary antibody was omitted and replaced with antibody 
diluent (RE7133, Novocastra Laboratories, UK) compatible with the 
immunohistochemical kit used. 
 
Evaluation of immunohistochemical staining 
Immunostained sections were evaluated by two observers (D.T., I.D.), blinded 
to the clinical and follow-up data, at a double-headed microscope. Positivity 
for K19, EpCAM or CD117 was defined as specific cytoplasmic and/or 
membrane immunostaining in ≥5% of tumour cells [14, 15, 21, 22, 33]. 
Immunopositive ductular cells, isolated or in strings, originating from 
surrounding non-neoplastic liver parenchyma and localized at the tumour 
periphery (Figure 1) were not counted. 
 
Follow up 
Sixty eight out of 89 patients were followed to the date of HCC-related death 
or to the end of follow-up (31 January 2011). The remaining 21 patients were 
lost to follow-up. Patients who underwent liver transplantation (n=9) were 
censored as alive on the day of transplantation. Mean follow-up was 
39.6±25.3 months (median 33 months).  
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Statistical Analysis 
Statistical analysis was performed using SPSS software, version 19.0 (SPSS, 
Chicago, IL) and assessed using the t-test, Pearson’s correlation test, or chi-
square test, as deemed appropriate.  Data were reported as mean± standard 
deviation (SD) if normally distributed and as median if not. Recurrence-free 
survival (RFS) and overall survival (OS) were calculated using the Kaplan-
Meier method, and differences in survival rate were compared using the Log 
Rank test. Deaths from causes other than HCC were not considered for 
inclusion in survival analysis. Multivariate analysis for OS and RFS was 
performed using the Cox-proportional hazards model with backward stepwise 
selection. Statistical significance was assumed when p<0.05.  
 
Results 
Clinical and pathological features of the study population 
Data on some clinico-pathological features were not available for all HCC 
cases (Table 1). Multi-nodular HCC (≥3 nodules) was present in 20/75 
(26.7%) cases while 37/72 (51.4%) had maximum tumour diameter >5cm. 
Microvascular invasion was observed in 39/70 HCC (55.7%) and 18/47 
(38.3%) showed portal vein thrombosis either on imaging or at the time of 
operation. In 27/54 (50%) and 8/56 (14.3%) HCC, liver capsule invasion or 
rupture was noted, accordingly. Distant metastasis was recorded in 6/36 
(16.7%) patients. Post-surgical staging according to TNM classification was 
as follows: stage I:24, II:15, III:32 (IIIa:23, IIIb:6, IIIc:3), IV:6 patients. In 12 
patients TNM staging could not be assessed due to missing data.   
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Correlation with clinico-pathological parameters 
KERATIN 19 
Keratin 19 was positive in 9/89 HCCs (10.11%)  (Figures 2A and 2C). K19 
immunostaining was noted in the cell membrane and/or cytoplasm of positive 
tumour cells. The percentage of K19-positive tumour cells ranged from 5% to 
90% (mean 24.4±32.54%, median 5%), (Figure 3B) and immunostaining was 
focal in the majority of cases (7/9). Only 3/9 K19-positive HCC focally showed 
positive tumour cells with morphological features suggestive of 
stem/progenitor cells (small, hyperchromatic nuclei and scant cytoplasm). 
Distinctive histological patterns of HCC (trabecular, solid, pseudoglandular, 
clear cell etc) did not correlate with K19-positivity. In K19-positive HCC with 
microvascular invasion, when intravascular tumour cells were included in the 
immunostained sections these were also K19-positive. 
 
Age, sex, tumour size >5cm, histological grade, TNM staging, presence of 
cirrhosis, multi-nodular disease, and viral aetiology did not correlate 
significantly with K19 protein expression (p>0.05). Of all parameters 
examined, only microvascular invasion tended to correlate with K19 
immunohistochemical expression (p=0.054) (Table 1). There were no 
statistical differences between HCC subgroups with focal or diffuse K19-
positivity. 
 
EpCAM 
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EpCAM expression was assessed in 78 HCC with tissue available for 
immunostaining (Figures 2B and 2D). EpCAM was positive in 12/78 HCCs 
(15.38%) (Figure 2B). EpCAM-specific immunostaining was membranous in 
positive tumour cells. The percentage of EpCAM-positive tumour cells ranged 
from 26% to 90% (mean 58.17±25.7, median 58.5%) (Figure 3C) and 
immunostaining was diffuse in the majority of cases (9/12). Two out of 12 
EpCAM-positive HCC focally showed positive tumour cells with morphological 
features suggestive of stem cells. Distinctive histological patterns of HCC did 
not correlate with EpCAM-positivity. In EpCAM-positive HCC with 
microvascular invasion, when intravascular tumour cells were included in the 
immunostained sections these were also EpCAM-positive. 
 
The correlation between EpCAM expression and clinical or pathological 
parameters was examined (Table 1). Age, tumour size >5cm, histological 
grade, presence of cirrhosis, multi-nodular disease, and viral aetiology 
showed no correlation with EpCAM protein expression (p>0.05). Of all 
parameters examined, only female gender was significantly correlated with 
EpCAM immunohistochemical expression (p=0.035). Three cases were 
positive for both K19 and EpCAM, 9 were K19-negative/EpCAM-positive, 5 
were K19-positive/EpCAM-negative, and 61 were negative for both markers. 
In serial sections of K19-positive/EpCAM-positive HCC, more tumour cells 
were positive for EpCAM compared to K19 (Figures 2A and 2B). Co-
expression of K19 and EpCAM occurred in the minority of tumour cells while 
the majority expressed only one of the two markers. 
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CD117 
CD117 was positive only in 3/81 (3.7%) cases in the cytoplasm of a small 
percentage of tumour cells (5%) (Figure 3D). Rare CD117-positive tumour 
cells showed morphological features of stem cells. CD117 immunopositivity 
did not show significant correlation with any of the clinico-pathological 
parameters examined (p>0.05) (Table 1). Two grade 3 CD117-positive HCC 
cases had multifocal disease with vascular invasion (portal vein thrombosis) 
and none of the cases had distant metastasis.  One grade 3 HCC showed co-
expression of K19 and CD117 and one grade 2 HCC showed co-expression 
of EpCAM and CD117. 
 
Survival analysis 
During follow-up, 43 out of 68 (63.2%) patients had recurrent disease and 
28/68 (41.2%) died of HCC-related causes. Two patients with K19-positive 
HCC were lost to follow-up. Among the remaining 7 patients with K19-positive 
HCC and complete follow-up data, 6 had tumour recurrence and 6 (85.7 %) 
died. Patients with K19-positive HCC had significantly decreased mean 
recurrence-free (RFS) (p<0.001) and overall survival (OS) (p=0.002) (Figure 
4) compared to those with K19-negative HCC. EpCAM or CD117 positivity did 
not show any significant correlation with neither RFS nor OS. When K19 and 
EpCAM co-expression was examined, patients with K19-positive/EpCAM-
positive HCC were characterized by significantly decreased RFS (p<0.001) 
and OS (p=0.001) compared to those with K19-negative/EpCAM-negative 
HCC. Although numbers are very small to draw robust conclusions, it is of 
interest that patients with HCC showing K19 and EpCAM co-expression (n=3) 
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had worse median RFS and median OS time compared to patients with HCC 
exhibiting K19-positivity only (n=5) (Log rank test, p=0.006 and p=0.001, 
respectively). 
 
a. Univariate analysis 
In univariate analysis, microvascular invasion (p=0.004) (Figure 5) and 
advanced TNM stage ≥ III (p=0.047) significantly correlated with decreased 
RFS. There was no relationship between tumour size >5cm (p=1.00), 
histological grade ≥3 (p=1.00), previous treatment (TACE or RFA) (p=0.133) 
and RFS. The presence of microvascular invasion was significantly 
associated with OS (p=0.029) (Figure 5). Tumour size >5cm (p=0.56), 
advanced histological grade (p=0.95), TNM stage ≥III (p=0.089), and previous 
treatment (TACE or RFA) (p=0.635) did not correlate significantly with OS. 
 
b. Multivariate analysis 
All variables that showed significant correlation with OS and RFS where 
included in the multivariate model building strategy. Cox-regression analysis 
revealed that K19- positivity was independently associated with RFS [Odds 
ratio (OR)=7.84, 95% confidence interval (CI)=2.658-22.912; p<0.001], 
whereas the presence of microvascular invasion and TNM stage ≥ III did not 
show independent association with RFS (Table 2). Similarly, K19-positivity 
was the only independent prognostic factor of OS (OR=3.845, 95% CI=1.401-
10.549; p=0.009, Table 3). 
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Discussion 
It is a well-established theory that human HCCs usually emerge during the 
process of multistep carcinogenesis [34]. Mature hepatocytes may transform 
creating pre-malignant lesions, namely dysplastic foci and dysplastic nodules, 
that may give rise to well differentiated early stage HCCs (early HCCs) [35]. 
Moreover, there is growing evidence that some HCCs derive from HPCs [34]. 
Primary liver carcinomas of combined type (combined HCC and 
cholangiocarcinoma) and HCCs that express progenitor cell markers are now 
recognised as examples of such alternative carcinogenic pathways [5, 36]. 
 
Two different theories have so far been expressed with regards to the 
presence of progenitor cell features in a tumour. Either, the cell of origin is a 
progenitor cell (maturation arrest theory) or alternatively, tumours de-
differentiate and acquire progenitor cell features during carcinogenesis 
(dedifferentiation theory) [7, 37-39]. The presence of progenitor cells in early 
premalignant lesions, such as dysplastic foci, is a strong argument in favour of 
a progenitor cell origin as opposed to dedifferentiation at a later stage [38]. 
 
The adverse prognosis of HCCs expressing HPC/stem cell markers may 
partly be attributed to the relationship between this subset of HCCs with 
invasion and metastasis-related gene expression. Up-regulation of invasion 
and metastasis-related genes, such as epithelial-mesenchymal transition 
(EMT) genes [7, 9], VIL2 (encoding ezrin) [7, 40], PLAUR (uPAR: urokinase 
plasminogen activator receptor) [7], and CD44 [7] has been demonstrated in 
HCCs with HPC features. Moreover, an association between high expression 
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levels of HPC markers in HCCs and tumour angiogenesis has recently been 
reported [4]. HCCs expressing "stemness"-related proteins are also 
characterized by increased telomere length, increased expression of hTERT 
and shelterin complex proteins, and increased chromosomal instability 
compared to conventional HCCs as shown in a recent study [11]. 
 
There are strong indications that K19 may be used as an HPC marker of 
prognostic significance [10, 17, 18]. Recently, a progenitor cell-derived HCC 
model was established in rats, which was characterized by a K19-positive 
gene signature that accurately predicted tumour recurrence and patient 
survival in human HCC [3]. Along these lines, an extensive gene-expression 
profiling study demonstrated the presence of a “hepatoblast-subtype” of 
human HCCs characterised by K19 expression [4]. There is growing evidence 
that K19-positivity is associated with increased expression of invasion–related 
proteins, both at protein and mRNA level [9, 19].  It still remains uncertain 
whether K19 expression implies that K19-positive HCCs actually carry 
stemness functions, as shown for the K19-positive ductular reactions of the 
regenerating liver, or that this expression is merely an epiphenomenon of poor 
differentiation [39].  
 
Several studies have reported K19 protein expression in HCCs varying from 
4.1% to 22.1% [5, 9, 12-15, 17, 20, 22, 36, 39, 41-46]. K19 expression has 
been correlated with poor histological differentiation [14, 15, 20], macro- and 
microvascular invasion [5, 9], advanced tumour stage and lymph node 
metastasis [13]. Recurrence-free survival and overall survival of patients with 
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K19-positive HCC has been shown to be reduced following surgical resection 
[4, 21], radio-frequency ablation [43] or liver-transplantation [22]. In addition, 
K19 immunopositivity in needle biopsies of HCCs has been recently identified 
as an independent predictor of overall patient survival [46]. There is limited 
evidence indicating increased resistance to chemotherapy in HCCs that 
express HPC markers, including K19 [45].  
 
In our study, K19, EpCAM and CD117 expression were examined in a series 
of HCCs with high incidence of HBV infection, which remains a major 
aetiological factor of chronic liver disease in Greek population [47]. The 
expression of K19 in our study group was 10.11% and showed no correlation 
with baseline characteristics such as tumour size, background chronic liver 
disease aetiology and histological grade. Among the baseline tumour 
characteristics, microvascular invasion was the only parameter that tended to 
correlate with K19 tissue expression, a finding that is concordant with 
previous evidence on the positive correlation of K19 expression with tumour 
angiogenesis and invasion [5, 9, 19]. The correlation of K19 with 
microvascular invasion did not reach statistical significance (p=0.054) most 
likely due to type II statistical error; examining a larger number of HCC could 
have shown a significant association. In univariate analysis, advanced TNM 
stage was correlated with RFS, while microvascular invasion with both RFS 
and OS. However, multivariate analysis indicated that K19-positivity was the 
only independent prognostic factor for both OS and RFS. Our findings 
highlight the prognostic importance of K19-positivity in a Caucasian patient 
cohort, as most relevant data to date come from Asian studies [5, 9, 12-14, 
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17, 20, 36, 39, 42-45], and are in keeping with those of a recent prospective 
study from Belgium on K19 immunohistochemical expression in 242 HCC 
from Caucasian patients [19] .   
 
Similarly, EpCAM has previously been identified as a marker of oval cells in 
rodent liver and stem/progenitor cells of adult human liver [25, 33, 48-53]. 
Recent studies, have shown that isolation of EpCAM(+) tumour cells from 
peripheral blood strongly correlates with prognosis in patients with HCC [54, 
55].  In a study by Yamashita et al [33], EpCAM and alpha-fetoprotein (AFP) 
expression was used to classify HCCs in four different subtypes with different 
prognosis and specific activated pathways depending on tumour cell origin. 
The categories proposed were EpCAM(+)/AFP(+) HCC as hepatic stem cell–
like HCC (HpSC-HCC), EpCAM(+)/AFP(-) HCC as bile duct epithelium–like 
HCC (BDE-HCC), EpCAM(-)/AFP(+) HCC as hepatocyte progenitor–like HCC 
(HP-HCC), and EpCAM(-)/AFP(-) HCC as mature hepatocyte–like HCC (MH-
HCC). The same study showed that other HPC markers such as K19 and 
CD117 were more abundantly expressed in HpSC-HCC. EpCAM(+)/AFP(+) 
HCC (HpSC-HCC) were characterized by poor prognosis whereas 
EpCAM(+)/AFP(-) HCC (MH-HCC) exhibited more favourable outcomes. In 
our study, isolated EpCAM expression did not significantly correlate with 
patient RFS or OS. This finding corroborates previous data showing that 
EpCAM expression is present in both hepatic stem-like and mature 
hepatocyte-like HCCs that are characterized by opposing clinical outcomes 
[33].  In our series K19/EpCAM co-expression in HCC was associated with 
worse RFS and OS compared to that of patients with HCC expressing K19 
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alone. However, this finding needs to be further assessed in a larger number 
of HCC as in our study group K19/EpCAM co-expression was only seen in 
3/78 HCC. CD117 was only expressed in a small percentage of tumour cells 
in only 3.7% of HCC and showed no significant association with prognostic 
features. 
 
In conclusion, our study showed that K19 immunopositivity is an independent 
predictor of RFS and OS in a cohort of Greek patients with HCC and could be 
used to stratify HCC according to tumour aggressiveness. Our study supports 
the prognostic role of K19 independently of other clinico-pathological 
parameters. Inclusion of K19 expression, as a marker of tumour 
aggressiveness in HCC, independently of tumour grade and stage, may 
increase the predictive value of the currently used scoring systems. The 
recent association between K19 expression and the epidermal growth factor 
receptor (EGFR) pathway in HCC [44] suggests a possible role for therapeutic 
use of EGFR inhibitors and may open the way for a more personalised 
treatment approach in HCC patients. 
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Legends to figures 
 
Figure 1. HCC grade 2: Few K19-positive tumour cells (arrows). K19-positive 
ductules at tumour periphery (black arrowheads) and intratumoural ductular 
cells (white arrowheads) are noted (x200) 
 
Figure 2. Serial sections of HCC positive for K19 (A) and EpCAM (B). Some 
positive tumour cells show morphological features of stem cells with smaller, 
dark nuclei and scant cytoplasm (arrow); C & D: Serial sections of HCC 
positive for K19 (C) but negative for EpCAM  (D), chromagen DAB (x200)  
 
Figure 3. Serial sections of well differentiated HCC (grade 2), trabecular 
pattern: A. H-E (x200), B. Keratin 19 immunoreactivity in >90% of tumour cells 
(x200), C: Moderately differentiated HCC (grade 3), solid pattern with EpCAM-
positivity in >90% of tumour cells (x200), D. A tumour cell (arrow) and mast 
cells (arrowhead) positive for CD117, chromagen DAB (x400). CD117-positive 
HCC showed isolated immunopositivity in 5% of tumour cells.  
 
Figure 4. A: K19 expression in relation to overall survival of HCC patients 
(Kaplan-Meier curves, log-rank test p=0.002); B: K19 expression in relation to 
recurrence-free survival of HCC patients (Kaplan-Meier curves, log-rank test 
p<0.001) 
 
Figure 5. A: Microvascular invasion in relation to overall survival of HCC 
patients (Kaplan-Meier curves, log-rank test, p=0.029); B. Microvascular 
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invasion in relation to recurrence-free survival of HCC patients (Kaplan-Meier 
curves, log-rank test, p=0.004) 
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Table 1. HCC patients’ characteristics and clinico-pathological parameters in 
correlation with K19 protein, EpCAM and CD117 expression. 
 
n: number of cases with the feature, N: total number of cases with available 
information on the feature, SD: standard deviation, K19: keratin 19,  EpCAM: 
Epithelial cell adhesion molecule, +: positive, -: negative 
immunohistochemical expression (p Values in CD117 were not included due 
to small number of positive cases)   
 
FEATURE 
K19+ 
n/N 
K19- 
n/N 
 
p 
 
 EpCAM+ 
n/N 
EpCAM- 
n/N 
 
p 
CD117+ 
 n/N 
  CD117- 
n/N 
 
Age 
(years, mean±SD) 
 
 
6712 
 
6711 
 
0.961 
 
 
70.48.2 
 
6511 
 
0.298 
 
70.5 
 
671 
Male gender 5/9 62/80 0.385  6/12 53/66 0.035 3/3 59/78 
Cirrhosis 5/7 41/66 1.000  4/9 39/55 0.059 1/2 40/65 
HBV 2/7 28/65 0.429  6/8 24/55 0.118 1/3 29/63 
HCV 2/7 19/65 1.000  1/8 20/55 0.155 0/3 21/63 
Alcohol 0/7 4/65 0.985  0/12 4/45 0.257 0/1 4/64 
≥3 nodules 3/7 17/68 0.331  3/11 15/57 0.638 1/3 17/67 
Tumour size > 5cm 5/7 32/65 1.000  7/12 25/54 0.294 1/3 35/65 
Tumour grade ≥ 3 4/9 38/80 0.862  6/12 33/66 1.000 1/3 38/78 
Microvascular invasion 7/8 32/62 0.054  6/11 30/53 0.901 2/3 35/62 
Portal vein thrombosis 3/5 15/42 0.357  2/6 15/36 0.082 2/2 16/43 
Capsular invasion 2/4 25/50 0.695  3/8 21/40 0.439 0/2 27/48 
Lymph node metastasis 1/7 2/59 0.290  0/12 3/51 0.464 0/3 2/57 
Distant metastasis 0/3 6/33 1.000  0/4 5/28 0.358 0/3 6/31 
TNM stage ≥ III 5/8 33/69 0.481  3/11 32/58 0.091 2/3 35/69 
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Table 2. Cox-regression analysis for recurrence-free survival of HCC patients 
 
 
Sig. OR 
   95.0% CI for OR 
Lower Upper 
Keratin 19 
protein expression 
 
0.000 7.804 2.658 22.912 
Microvascular invasion 
 
0.099 2.194 0.863 5.576 
TNM Stage ≥ III 
 
0.390 1.461 0.615 3.468 
 
Sig.: significance, OR: odds ratio, CI: confidence interval 
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Table 3. Cox-regression analysis for overall survival of HCC patients 
 
Sig. OR 
   95.0% CI for OR 
Lower Upper 
 
Microvascular 
invasion 
 
 
0.208 
 
1.832 
 
0.715 
 
4.696 
Keratin 19 
protein expression 
0.009 3.845 1.401 10.549 
 
 
Sig.: significance, OR: odds ratio, CI: confidence interval 
 
